[Dissociation between the effect on myeloblastoma and the hematologic effect of Ara-C therapy: report of an autopsied myeloblastic leukemia case with around five-year course].
Koyama
T
T
Tohda
S
S
Kamiyama
T
T
Suzuki
T
T
Nagata
K
K
Nakamura
Y
Y
Miura
O
O
Maruyama
Y
Y
Kato
A
A
Murakami
N
N
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology; D003561:Cytarabine / Q000008:administration & dosage / Q000494:pharmacology; D003630:Daunorubicin / Q000008:administration & dosage; D004351:Drug Resistance; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy*; D015122:Mercaptopurine / Q000008:administration & dosage; D012074:Remission Induction; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014594:Uterine Neoplasms / Q000097:blood / Q000188:drug therapy
D003561:Cytarabine; D015122:Mercaptopurine; D003630:Daunorubicin